文献速递重症综合管理与镇静镇痛

口服激发试验与常规护理评估重症住院患者低风险青霉素过敏(ORACLE):一项安全性及可行性初步随机对照试验

Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial.
PubMed 文献 · Intensive Care Med · 2024-05-13
一句话结论在4个ICU中,对PEN-FAST评分<3的低风险青霉素过敏标签患者行直接肠内激发,阳性率2.5%,无抗生素相关严重不良事件。

该初步随机对照试验在澳大利亚墨尔本4个ICU纳入PEN-FAST风险评分<3的低风险青霉素过敏标签患者,1:1随机分为青霉素(250 mg阿莫西林或相关青霉素)直接肠内激发组与常规护理组(两组随机化后均观察2小时),干预组在转出ICU后重复激发。共筛查533例,130例(24.4%)符合条件,80/130(61.5%)入组,年龄中位数64.5岁(IQR 53.5, 74),PEN-FAST中位数1(IQR 0,1),40例(50%)随机至直接肠内激发。激发阳性率2.5%,未发现抗生素相关严重不良事件;32/40(80%)接受重复激发(零阳性)。随机化后,干预组13例(32%)vs 对照组4例(10%)接受青霉素(OR 4.33 [1.27, 14.78],p=0.019)。作者认为这些发现支持对PEN-FAST评估为低风险青霉素过敏的重症患者行直接肠内激发的安全性、有效性和可行性。

要点

  • 在4个ICU中,PEN-FAST评分<3的低风险青霉素过敏标签重症患者接受直接肠内激发(250 mg阿莫西林或相关青霉素),激发阳性率为2.5%。
  • 直接肠内激发组未发现抗生素相关严重不良事件,后续重复激发(32/40,80%)均为零阳性。
  • 随机化后干预组13例(32%)vs 对照组4例(10%)接受青霉素(OR 4.33 [1.27, 14.78],p=0.019)。
  • 筛查533例中130例(24.4%)符合条件、80/130(61.5%)入组,作者认为需更宽松的入选标准并将过敏评估整合入常规ICU流程以优化去标签。
  • 两组随机化后均观察2小时,并在每次激发/观察后24小时和5天进行随访。

适用人群与场景

  • 澳大利亚墨尔本4个ICU中带有低风险青霉素过敏标签(PEN-FAST风险评分<3)的同意患者。

诊断标准与关键阈值

  • 低风险青霉素过敏标签定义为PEN-FAST风险评分<3。

处置流程与药物剂量

  • 直接肠内激发组给予青霉素250 mg阿莫西林或相关青霉素,肠内给药;对照组接受常规护理;两组随机化后均观察2小时。
  • 干预组在转出ICU后重复激发;每次激发/观察后24小时和5天进行随访。

研究设计与关键结果

  • 研究类型:初步安全性及可行性随机对照试验;4个ICU(澳大利亚墨尔本);筛查533例,130例(24.4%)符合条件,80/130(61.5%)入组;年龄中位数64.5岁(IQR 53.5, 74),PEN-FAST中位数1(IQR 0,1);40例(50%)随机至直接肠内激发。
  • 激发阳性率2.5%;未发现抗生素相关严重不良事件;32/40(80%)接受重复激发,零阳性。
  • 随机化后,干预组13例(32%)vs 对照组4例(10%)接受青霉素(OR 4.33 [1.27, 14.78],p=0.019)。

证据类型、等级与局限

  • 证据类型:初步随机对照试验;作者认为这些发现支持直接肠内激发对PEN-FAST评估为低风险青霉素过敏的重症患者的安全性、有效性和可行性;重复激发的阴性结果确认了无假阴性结果。
  • 局限:筛查与入组比例相对较低,提示需要更宽松的入选标准并将过敏评估整合入常规ICU流程,以优化重症患者的过敏去标签。

对床旁实践的改变

  • 对ICU中PEN-FAST评分<3的低风险青霉素过敏标签患者,直接肠内激发(250 mg阿莫西林或相关青霉素)未发现抗生素相关严重不良事件,激发阳性率2.5%。
  • 作者认为这些发现支持直接肠内激发的安全性、有效性和可行性;作者建议采用更宽松的入选标准并将过敏评估整合入常规ICU流程,以优化重症患者的过敏去标签。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Critically ill patients are vulnerable to penicillin allergy labels that may be incorrect. The validity of skin testing in intensive care units (ICUs) is uncertain. Many penicillin allergy labels are low risk, and validated tools exist to identify those amenable to direct oral challenge. This pilot randomised controlled trial explored the feasibility, safety, and validity of direct enteral challenge for low-risk penicillin allergy labels in critical illness.

METHODS: Consenting patients with a low-risk penicillin allergy label (PAL) (PEN-FAST risk assessment score < 3) in four ICUs (Melbourne, Australia) were randomised 1:1 to penicillin (250 mg amoxicillin or implicated penicillin) direct enteral challenge versus routine care (2-h post-randomisation observation for each arm). Repeat challenge was performed post -ICU in the intervention arm. Patients were reviewed at 24 h and 5 days after each challenge/observation.

RESULTS: We screened 533 patients. 130 (24.4%) were eligible and 80/130 (61.5%) enrolled (age median 64.5 years (interquartile range, IQR 53.5, 74), PEN-FAST median 1 (IQR 0,1)), with 40 (50%) randomised to direct enteral challenge. A positive challenge rate of 2.5% was identified. No antibiotic-associated serious adverse events were identified. 32/40 (80%) received a repeat challenge (zero positive). Post-randomisation, 13 (32%) of the intervention arm and 4 (10%) of the control arm received penicillin (odds ratio, OR 4.33 [1.27, 14.78] p = 0.019).

CONCLUSION: These findings support the safety, validity, and feasibility of direct enteral challenge for critically ill patients with PEN-FAST assessed low-risk penicillin allergy. The absence of false negative results was confirmed by subsequent negative repeat challenges. A relatively low recruitment to screened ratio suggests that more inclusive eligibility criteria and integration of allergy assessment into routine ICU processes are needed to optimise allergy delabelling in critical illness.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rose MT, Holmes NE, Eastwood GM, et al. Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial. Intensive Care Med. 2024. PMID: 38739277. doi:10.1007/s00134-024-07448-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。